Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.76 USD | +0.91% | -1.92% | -17.59% |
Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
Apr. 19 | BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89 | MT |
Evolution of the average Target Price on Gilead Sciences, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Gilead Sciences, Inc.
BMO Capital | |
Leerink Partners | |
UBS | |
Goldman Sachs | |
Morgan Stanley | |
Wells Fargo Securities | |
Mizuho Securities | |
Truist Securities | |
RBC Capital Markets | |
Oppenheimer | |
Piper Sandler | |
TD Cowen | |
Cantor Fitzgerald | |
Barclays | |
Deutsche Bank Securities | |
BofA Securities | |
HSBC | |
SVB Securities LLC | |
Cowen | |
Maxim | |
JPMorgan Chase | |
Argus | |
SVB Leerink | |
Credit Suisse | |
Bernstein | |
Redburn | |
DZ BANK | Elmar Kraus |
EPS Revisions
- Stock Market
- Equities
- GILD Stock
- Consensus Gilead Sciences, Inc.